Pharmacological study of piroheptine, a new antiparkinson drug. II. Anticholinergic, antihistaminic, and psychopharmacological actions and toxicity.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000633:toxicity; D001285:Atropine / Q000494:pharmacology; D002490:Central Nervous System / Q000187:drug effects; D004285:Dogs; D005260:Female; D005333:Fetus / Q000187:drug effects; D005750:Gastric Juice / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009184:Mydriatics / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology*; D011398:Promethazine / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D011919:Rats, Inbred Strains; D014282:Trihexyphenidyl / Q000494:pharmacology
D000978:Antiparkinson Agents; D006634:Histamine H1 Antagonists; D009184:Mydriatics; D010276:Parasympatholytics; D011759:Pyrrolidines; D014282:Trihexyphenidyl; D001285:Atropine; D011398:Promethazine